{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:50:57Z","timestamp":1763754657548,"version":"3.45.0"},"reference-count":10,"publisher":"Oncology Nursing Society (ONS)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"DOI":"10.1188\/25.cjon.334-338","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T17:19:37Z","timestamp":1755019177000},"source":"Crossref","is-referenced-by-count":0,"title":["Standardizing Liposomal Doxorubicin Administration: Titration Protocol"],"prefix":"10.1188","member":"1302","published-online":{"date-parts":[[2025,8,2]]},"reference":[{"key":"1","unstructured":"Baxter International. (2022). Doxil\u00ae (doxorubicin hydrochloride liposome injection) [Package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/050718Orig1s060lbl.pdf"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Brown, S.G.A. (2004). Clinical features and severity grading of anaphylaxis. Journal of Allergy and Clinical Immunology, 114(2), 371\u2013376. https:\/\/doi.org\/10.1016\/j.jaci.2004.04.029","DOI":"10.1016\/j.jaci.2004.04.029"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Chanan-Khan, A., Szebeni, J., Savay, S., Liebes, L., Rafique, N.M, Alving, C.R., & Muggia, F.M. (2003). Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil\u00ae): Possible role in hypersensitivity reactions. Annals of Oncology, 14(9), 1430\u20131437. https:\/\/doi.org\/10.1093\/annonc\/mdg374","DOI":"10.1093\/annonc\/mdg374"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Ingen-Housz-Oro, S., Pham-Ledard, A., Brice, P., Lebrun-Vignes, B., Zehou, O., Reitter, D., . . . Beylot-Barry, M. (2017). Immediate hypersensitivity reaction to pegylated liposomal doxorubicin: Management and outcome in four patients. European Journal of Dermatology, 27(3), 271\u2013274. https:\/\/doi.org\/10.1684\/ejd.2017.2986","DOI":"10.1684\/ejd.2017.2986"},{"key":"5","unstructured":"Institute for Healthcare Improvement. (n.d.). How to improve: Model for improvement. Retrieved May 3, 2025, from https:\/\/www.ihi.org\/library\/model-for-improvement"},{"key":"6","unstructured":"Langley, G.L., Moen, R.D., Nolan, K.M., Nolan, T.W., Norman, C.L., & Provost, L.P. (2009). The improvement guide: A practical approach to enhancing organizational performance (2nd ed.). Jossey-Bass."},{"key":"7","unstructured":"National Cancer Institute Cancer Therapy Evaluation Program. (2017). Common Terminology Criteria for Adverse Events [v.5.0]. http:\/\/bit.ly\/44YF8Q2"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Szebeni, J., F\u00fcl\u00f6p, T., D\u00e9zsi, L., Metselaar, B., & Storm, G. (2016). Liposomal doxorubicin: The good, the bad and the not-so-ugly. Journal of Drug Targeting, 24(9), 765\u2013767. https:\/\/doi.org\/10.3109\/1061186x.2016.1172591","DOI":"10.3109\/1061186X.2016.1172591"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Yamaguchi, S., Yahata, H., Okugawa, K., Kodama, K., Yagi, H., Yasunaga, M., . . . Kato, K. (2021). Hypersensitivity reaction to pegylated liposomal doxorubicin administration for Mullerian carcinoma in Japanese women. Journal of Obstetrics and Gynaecology Research, 47(4), 1544\u20131548. https:\/\/doi.org\/10.1111\/jog.14680","DOI":"10.1111\/jog.14680"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Zhang, K.-P., Fang, X., Zhang, Y., & Chao, M. (2021). The prognosis of cancer patients undergoing liposomal doxorubicin-based chemotherapy: A systematic review and meta-analysis. Medicine, 100(34), e26690. https:\/\/doi.org\/10.1097\/MD.0000000000026690","DOI":"10.1097\/MD.0000000000026690"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/publications-research\/cjon\/29\/4\/standardizing-liposomal-doxorubicin-administration-titration","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:47:37Z","timestamp":1763754457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/29\/4\/standardizing-liposomal-doxorubicin-administration-titration"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":10,"URL":"https:\/\/doi.org\/10.1188\/25.cjon.334-338","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}